Close Menu

NEW YORK ─ DiaSorin said Saturday it has received US Food and Drug Administration Emergency Use Authorization for the Liaison SARS-CoV-2 S1/S2 IgG serology assay, which identifies the presence of IgG antibodies in people who have been infected with SARS-CoV-2.

Saluggia, Italy-based DiaSorin also said that it recently inked a contract with the US Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) to obtain funding to making the test available in the US. Financial terms of the contract were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

Amid the COVID-19 pandemic, hospitals and intensive care units around the world have been overwhelmed by unprecedented levels of demand. 

Sponsored by
LGC SeraCare Life Sciences

As we pass the one-year anniversary of both the COVID-19 pandemic and the first Emergency Use Authorized SARS-CoV-2 PCR detection assays, there remains significant opportunity for clinical laboratories to advance testing and support improved patient management.

Sponsored by

This webinar will present the details of a COVID-19 saliva screening program that has been implemented at more than 90 different colleges, universities, private schools, and nursing homes across New York state.